SARS-CoV-2 受体结合域诱导的中和抗体反应。
Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.
机构信息
Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
出版信息
Hum Vaccin Immunother. 2021 Mar 4;17(3):654-655. doi: 10.1080/21645515.2020.1814098. Epub 2020 Sep 29.
Abstract
A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.
摘要
一种安全有效的疫苗候选物对于当前由 SARS-CoV-2 引起的 COVID-19 大流行是迫切需要的。在这里，我们报告了重组 SARS-CoV-2 RBD 蛋白免疫能够在小鼠中引发强烈的抗体反应和有效的中和能力，这是通过使用活的或假型 SARS-CoV-2 中和测定来衡量的。
相似文献
1
Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.
Hum Vaccin Immunother. 2021 Mar 4;17(3):654-655. doi: 10.1080/21645515.2020.1814098. Epub 2020 Sep 29.
2
Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Vaccine. 2020 Oct 27;38(46):7205-7212. doi: 10.1016/j.vaccine.2020.09.058. Epub 2020 Sep 22.
3
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
Vaccine. 2020 Nov 3;38(47):7533-7541. doi: 10.1016/j.vaccine.2020.09.061. Epub 2020 Sep 22.
4
SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Emerg Microbes Infect. 2020 Dec;9(1):2076-2090. doi: 10.1080/22221751.2020.1821583.
5
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.
6
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Signal Transduct Target Ther. 2020 Nov 27;5(1):282. doi: 10.1038/s41392-020-00402-5.
7
Covalent coupling of Spike's receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2.
Sci Rep. 2022 Jan 13;12(1):692. doi: 10.1038/s41598-021-03675-0.
8
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Nature. 2020 Oct;586(7830):572-577. doi: 10.1038/s41586-020-2599-8. Epub 2020 Jul 29.
9
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
mSphere. 2021 Aug 25;6(4):e0057121. doi: 10.1128/mSphere.00571-21. Epub 2021 Jul 28.
10
Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies.
Biochem Biophys Res Commun. 2021 Jan 29;538:192-203. doi: 10.1016/j.bbrc.2020.10.012. Epub 2020 Oct 10.
引用本文的文献
1
Enhanced Immunogenicity and Protective Effects against SARS-CoV-2 Following Immunization with a Recombinant RBD-IgG Chimeric Protein.
Vaccines (Basel). 2024 Mar 27;12(4):356. doi: 10.3390/vaccines12040356.
2
Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Appl Microbiol Biotechnol. 2023 May;107(9):2983-2995. doi: 10.1007/s00253-023-12490-8. Epub 2023 Mar 29.
3
Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response.
Vaccines (Basel). 2022 Oct 30;10(11):1839. doi: 10.3390/vaccines10111839.
4
Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2.
Vaccines (Basel). 2021 Jul 9;9(7):768. doi: 10.3390/vaccines9070768.
本文引用的文献
1
The Challenges of Vaccine Development against a New Virus during a Pandemic.
Cell Host Microbe. 2020 May 13;27(5):699-703. doi: 10.1016/j.chom.2020.04.021.
2
Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus.
Adv Funct Mater. 2019 Jul 11;29(28):1807616. doi: 10.1002/adfm.201807616. Epub 2019 Apr 12.
3
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.
Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.
4
The SARS-CoV-2 Vaccine Pipeline: an Overview.
Curr Trop Med Rep. 2020;7(2):61-64. doi: 10.1007/s40475-020-00201-6. Epub 2020 Mar 3.
5
Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates.
ACS Infect Dis. 2016 May 13;2(5):361-76. doi: 10.1021/acsinfecdis.6b00006. Epub 2016 Apr 11.
6
Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge.
EBioMedicine. 2015 Aug 18;2(10):1438-46. doi: 10.1016/j.ebiom.2015.08.031. eCollection 2015 Oct.
7
Fc-fusion proteins: new developments and future perspectives.
EMBO Mol Med. 2012 Oct;4(10):1015-28. doi: 10.1002/emmm.201201379. Epub 2012 Jul 26.
8
SARS vaccine development.
Emerg Infect Dis. 2005 Jul;11(7):1016-20. doi: 10.3201/1107.050219.
Zotero 插件